Oxford Immunotec Global PLC (NASDAQ:OXFD) was downgraded by TheStreet from a “hold” rating to a “sell” rating in a research report issued on Monday.

Several other equities analysts have also recently weighed in on OXFD. BTIG Research reaffirmed a “buy” rating and set a $17.00 target price on shares of Oxford Immunotec Global PLC in a research note on Sunday, September 11th. Zacks Investment Research cut Oxford Immunotec Global PLC from a “hold” rating to a “sell” rating in a research note on Friday, August 5th.

Oxford Immunotec Global PLC (NASDAQ:OXFD) remained flat at $14.57 on Monday. 100,652 shares of the company were exchanged. The firm has a 50-day moving average of $13.51 and a 200 day moving average of $10.72. The firm’s market cap is $329.31 million. Oxford Immunotec Global PLC has a one year low of $7.73 and a one year high of $14.73.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings data on Tuesday, November 1st. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.33) by $0.15. The firm had revenue of $26.10 million for the quarter, compared to the consensus estimate of $24.79 million. Oxford Immunotec Global PLC had a negative return on equity of 28.36% and a negative net margin of 30.17%. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.20) EPS. On average, analysts forecast that Oxford Immunotec Global PLC will post ($1.16) EPS for the current fiscal year.

In related news, Director Richard A. Sandberg sold 12,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $14.17, for a total value of $170,040.00. Following the completion of the sale, the director now owns 31,774 shares of the company’s stock, valued at approximately $450,237.58. The sale was disclosed in a document filed with the SEC, which is available at this link. 7.58% of the stock is owned by corporate insiders.

Large investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in shares of Oxford Immunotec Global PLC during the third quarter valued at approximately $116,000. Prudential Financial Inc. purchased a new stake in shares of Oxford Immunotec Global PLC during the third quarter valued at approximately $139,000. SG Americas Securities LLC purchased a new stake in shares of Oxford Immunotec Global PLC during the second quarter valued at approximately $114,000. Societe Generale purchased a new stake in shares of Oxford Immunotec Global PLC during the second quarter valued at approximately $114,000. Finally, American International Group Inc. boosted its stake in shares of Oxford Immunotec Global PLC by 8.3% in the second quarter. American International Group Inc. now owns 12,779 shares of the company’s stock valued at $115,000 after buying an additional 982 shares during the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

WARNING: This article was first published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2016/11/23/thestreet-lowers-oxford-immunotec-global-plc-oxfd-to-sell.html.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.

5 Day Chart for NASDAQ:OXFD

Receive News & Stock Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related stocks with our FREE daily email newsletter.